Related Experiment Video
Updated: Jul 5, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renin inhibitors, clinical experience.
Dirk Westermann1, Roland Schmieder, Heinz-Peter Schultheiss
1Department of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany.
Journal of Molecular Medicine (Berlin, Germany)
|April 26, 2008
Summary
Direct renin inhibitors, like aliskiren, offer a new way to manage high blood pressure. Clinical trials show their potential in treating hypertension, heart failure, and diabetic nephropathy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- The renin-angiotensin system (RAS) is a key target for managing arterial hypertension.
- Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are established RAS inhibitors with proven benefits in reducing blood pressure, preventing end-organ damage, and decreasing mortality.
- Early attempts at direct renin inhibition were limited by poor bioavailability and short duration of action.
Purpose of the Study:
- To review clinical trials of aliskiren, a novel direct renin inhibitor.
- To discuss the current role of aliskiren in treating arterial hypertension.
- To explore potential new applications for aliskiren in heart failure and diabetic nephropathy.
Main Methods:
- Review of clinical studies involving aliskiren.
- Analysis of aliskiren's efficacy and safety in arterial hypertension.
- Exploration of preclinical and clinical data for heart failure and diabetic nephropathy.
Main Results:
- Aliskiren represents a new class of orally available, non-peptide direct renin inhibitors.
- Clinical trials have evaluated aliskiren's effectiveness in patients with arterial hypertension.
- Emerging data suggests potential benefits in managing heart failure and diabetic nephropathy.
Conclusions:
- Aliskiren provides a third distinct mechanism for inhibiting the renin-angiotensin system.
- Aliskiren is established in the contemporary treatment of arterial hypertension.
- Further research is warranted to define the role of aliskiren in heart failure and diabetic nephropathy.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...